Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)

Use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)

US Patent 10189856 · Granted Jan 29, 2019

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination 2025
Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination 2025
Substituted pyrazolo piperidine carboxylic acids2025
Diazabicyclic substituted imidazopyrimidines and their use for the treatment of 2024
Treatment of cardiopulmonary disorders2024
Substituted 5-fluoro-1H-pyrazolopyridines and their use2024
Substituted 5-fluoro-1H-pyrazolopyridines and their use2024
Substituted 5-fluoro-1H-pyrazolopyridines and their use2024
Substituted S-alaninate derivatives2024
Combination containing sGC stimulators and mineralocorticoid receptor antagonist2023
Method of identifying a subgroup of patients suffering from dcSSc which benefits2022
Use of non-steroidal mineralocorticoid receptor antagonists alone or in combinat2022